Key Points
- Takeda CEO Julie So-Young Kim sold 89,090 shares at an average price of $17.10, worth approximately $1.52 million. The sale covered tax-withholding obligations from vested equity awards, and she retained 391,489 shares.
- Several other senior insiders also reduced their holdings, which could weigh on investor sentiment, although the transactions were reportedly tied to tax obligations rather than discretionary selling.
- Takeda shares opened at $17.42, with a market capitalization of about $55.82 billion. Analysts collectively rate the stock “Hold,” with two Buy, one Hold and one Sell rating.
Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Elaine Mary Shannon sold 3,978 shares of the company's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $68,023.80. Following the transaction, the insider directly owned 63,333 shares in the company, valued at approximately $1,082,994.30. This represents a 5.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Takeda Pharmaceutical Stock Down 0.3%
Shares of NYSE TAK opened at $17.42 on Thursday. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $55.82 billion, a PE ratio of 51.24 and a beta of -0.08. The firm's 50-day moving average is $16.49 and its 200-day moving average is $17.13. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.90.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The firm had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Equities analysts expect that Takeda Pharmaceutical Co. will post 3.01 EPS for the current year.
Takeda Pharmaceutical News Summary
Here are the key news stories impacting Takeda Pharmaceutical this week:
- Positive Sentiment: Insiders continued to hold substantial positions after the transactions, suggesting the sales do not necessarily reflect a loss of confidence in Takeda’s business or outlook. The filings state that the shares were sold to cover tax withholding obligations related to vested equity awards. SEC insider filing
- Neutral Sentiment: Analyst sentiment remains mixed: ratings include two Buys, one Hold and one Sell, resulting in an overall “Hold” consensus. Recent institutional buying has also provided some support, but those purchases were relatively small compared with Takeda’s market capitalization. Takeda stock analysis
- Negative Sentiment: Multiple senior executives and insiders sold a combined 399,? shares at an average price of $17.10. CEO Julie So-Young Kim sold 89,090 shares, Andrew Stewart Plump sold 165,393 shares and General Counsel Natalie Anne Marie Furney sold 30,868 shares. Other insiders also reduced their holdings by approximately 5.9% to 17.8%, which could weigh on investor sentiment despite the tax-related explanation. Takeda insider sales report
Analysts Set New Price Targets
TAK has been the subject of several analyst reports. Weiss Ratings lowered Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, July 30th. Zacks Research upgraded Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Finally, Wall Street Zen upgraded Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a report on Saturday, July 18th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Takeda Pharmaceutical has a consensus rating of "Hold".
Check Out Our Latest Analysis on Takeda Pharmaceutical
Hedge Funds Weigh In On Takeda Pharmaceutical
Several hedge funds have recently made changes to their positions in TAK. Renaissance Technologies LLC lifted its stake in Takeda Pharmaceutical by 14.2% in the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company's stock valued at $55,358,000 after acquiring an additional 370,800 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Takeda Pharmaceutical in the fourth quarter valued at about $998,000. Quantinno Capital Management LP raised its holdings in Takeda Pharmaceutical by 20.6% in the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company's stock valued at $23,878,000 after acquiring an additional 219,999 shares during the period. Sivia Capital Partners LLC acquired a new stake in Takeda Pharmaceutical during the 2nd quarter worth approximately $351,000. Finally, Bleakley Financial Group LLC lifted its holdings in shares of Takeda Pharmaceutical by 19.0% during the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company's stock worth $7,993,000 after buying an additional 68,844 shares in the last quarter. 9.17% of the stock is owned by institutional investors.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
